Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jorge Rivero-Becerra

Interventional Pain Medicine Pittsburgh, PA Medical Doctor

NPI 1396780409 CMS profile 688095

363 Vanadium Rd, Suite 106, Pittsburgh, PA 15243

Open in the dashboard

General payments

$12,353

768 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jorge Rivero-Becerra of Pittsburgh, PA is reported in the CMS Open Payments database as having received $12,353 across 768 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,298 59
2024 General $2,084 89
2023 General $1,668 101
2022 General $1,807 113
2021 General $1,401 109
2020 General $1,335 90
2019 General $2,760 207

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jorge Rivero-Becerra
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jorge Rivero-Becerra were reported at $1,298. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jorge Rivero-Becerra Interventional Pain Medicine median Middle half National median
2019 $2,760 $684 $216–$2,079 $163
2020 $1,335 $382 $122–$1,109 $114
2021 $1,401 $552 $167–$1,554 $132
2022 $1,807 $605 $187–$1,924 $149
2023 $1,668 $671 $195–$1,915 $160
2024 $2,084 $684 $206–$1,837 $164
2025 $1,298 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Collegium Pharmaceutical, Inc. $1,763 152 payments
  2. AbbVie, Inc. $1,589 86 payments
  3. Abbott Laboratories $1,429 25 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,335 101 payments
  5. Boston Scientific Corporation $903 36 payments
  6. Scilex Pharmaceuticals Inc. $859 62 payments
  7. Indivior Inc. $761 44 payments
  8. TerSera Therapeutics LLC $425 21 payments
  9. Horizon Therapeutics plc $399 37 payments
  10. Pfizer Inc. $295 31 payments
  11. Other $2,595 173 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,334 764 payments
  2. Education $19 4 payments
Products named General payments · program years 2019–2025
  1. XTAMPZA $1,387 122 payments
  2. RELISTOR Gastroenterology $1,335 101 payments
  3. UBRELVY $1,250 64 payments
  4. RELISTOR Gastroenterology $882 67 payments
  5. QULIPTA $840 47 payments
  6. SUBLOCADE $532 32 payments
  7. ZTLido $441 39 payments
  8. PROCLAIM $431 6 payments
  9. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $418 23 payments
  10. BELBUCA $376 30 payments
  11. Other $5,556 326 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

8,816

Median for Interventional Pain Management: 1,220

Drug cost

$548,540

Median for Interventional Pain Management: $39,344

Branded share of claims

49.6%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 156 $98,918
Oxycontin Oxycodone Hcl Brand 114 $85,847
Relistor Methylnaltrexone Bromide Brand 26 $58,448
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,927 $39,284
Movantik Naloxegol Oxalate Brand 92 $38,232
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 227 $30,593
Buprenorphine Generic 78 $25,478
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,171 $24,764
Oxymorphone Hcl Er Oxymorphone Hcl Brand 23 $17,314
Belbuca Buprenorphine Hcl Brand 24 $15,405

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$110,901

Of which drugs: $2,503

Medicare patients

191

Average age 70

Services billed

3,148

116 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Depression 37%
Diabetes 30%
Osteoporosis 19%
Ischemic heart disease 18%
COPD 18%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 80 1,605 $142
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 40 64 $18
Injection, bupivicaine, not otherwise specified, 0.5 mg J0665 Office 18 59 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
$244 26 —
UBRELVY
$235 — —
QULIPTA
$181 — —
XTAMPZA
$115 156 —
BELBUCA
$94 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

768 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record